Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05440643 · ClinicalTrials.gov registry record · Phase 1
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
A Phase 1 study of Peanut Allergy, sponsored by ALK-Abelló A/S.
- Active
- Registry status
- Phase 1
- Development phase
- 192
- Enrollment target
- 20
- Study locations
NCT05440643: Active Phase 1 study of Peanut Allergy, sponsored by ALK-Abelló A/S.
NCT05440643 is a Phase 1 study of Peanut Allergy that is active but no longer recruiting, run by ALK-Abelló A/S. The registered enrollment target is 192 participants, roughly in line with the 199-participant average among 13 other Peanut Allergy trials with a reported enrollment target. The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05440643, a Phase 1 study of Peanut Allergy, is active but no longer recruiting, sponsored by ALK-Abelló A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 192 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical research study investigates the safety, tolerability and efficacy of a peanut SLIT-tablet in adults, adolescents, and children with peanut allergy.
Primary Outcome
The dose tolerability response rate is defined as the percentage of subjects who experience at most moderate local application site reactions after the last peanut SLIT-tablet intake of the dose step. Local application site reactions are treatment-related adverse events occurring in close proximity to the application site of the SLIT-tablet with a temporal relationship to tablet administration.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Peanut SLIT-tablet
Study Locations (20)
California
- Children's Hospital of Los Angeles - USC School of Medicine - Los Angeles
- UCLA - Pediatrics - Los Angeles
- Stanford University - Lucile Packard Children's Hospital - Palo Alto
- Peninsula Research Associates (PRA) - Rolling Hills Estates
- Eastern Virginia Medical School - Children's Hospital - San Diego
- Allergy & Asthma Clinical Research - Walnut Creek
Florida
- Quality Research of South Florida - Hialeah
- MOORE-PH Dermatology - Clinical Research - Tampa
- USF Asthma Allergy and Immunology Clinical Research Unit - Tampa
Illinois
- Ann Robert H. Lurie Childrens Hospital of Chicago - Chicago
- Rush University - Chicago
- Sneeze, Wheeze, & Itch Associates, LLC - Normal
Maryland
- Johns Hopkins University School of Medicine - Baltimore
- Asthma, Allergy and Sinus Center - White Marsh
Arkansas
- Arkansas Children's Hospital - Little Rock
Colorado
- Children's Hospital Colorado - Aurora
Georgia
- Center for Advance Pediatrics - Atlanta
Kentucky
- Family Allergy Asthma Research Institute - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2022-09-07 |
| Est. Completion | 2026-04 |
| Phase | Phase 1 |
What the registry record for NCT05440643 still lists
NCT05440643 is an interventional study that assigns participants to a tested intervention. The registered 192 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 199-participant average among 13 other Peanut Allergy trials with a reported enrollment target.
The record links to 1 condition, with Peanut Allergy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05440643 names 20 study sites across 10 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT05440643 about?
NCT05440643 is a clinical study titled "Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy". This clinical research study investigates the safety, tolerability and efficacy of a peanut SLIT-tablet in adults, adolescents, and children with peanut allergy.
What is the current status of trial NCT05440643?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 192 participants. The study started on 2022-09-07. Estimated completion is 2026-04.
What conditions does trial NCT05440643 study?
This clinical trial studies the following conditions: Peanut Allergy.
What interventions are being tested in trial NCT05440643?
The interventions under investigation include: Placebo (OTHER), Peanut SLIT-tablet (BIOLOGICAL).
Who is sponsoring clinical trial NCT05440643?
This trial is sponsored by ALK-Abelló A/S, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05440643 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peanut Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05440643's enrollment target sits among peer trials
192 6th of 13 higher than 8 of 13 other Peanut Allergy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peanut Allergy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine
COMPLETED · Phase 1
-
Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial
COMPLETED · Phase 1
-
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
RECRUITING · Phase 2
-
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
RECRUITING · Phase 3
-
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
- NCT02535702 · 192 participants · NA
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
- NCT03622359 · 192 participants · NA
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI